OJRA  Vol.4 No.1 , February 2014
Rheumatoid Factor and Anti Citrulinated Peptide. Relation with Remission and Progression in Rheumatoid Arthritis with Biologic Agent Therapy, during a One-Year Follow-Up
Abstract: The aim of this study is to assess the variations of the RF and ACCP in RA patients treated with biologics in actual clinical practice (real) conditions for a one-year follow-up from the first biologic medication. The evaluated patients with a diagnosis of RA, according to the American College of Rheumatology (ACR) 1987 were selected from the outpatient consult of Rheumatology of the “Hospital de Sant Pau” during one month (November 2012). We collected and analyzed data from 41 patients with RA and positivity for RF and/or ACCP. Of the 41 patients had given FR and ACCP at 3, 6 and 12 months respectively in 18 and 10 patients. In 22 patients had given DAS 28 at 3, 6 and 12 months respectively. The mean age of the sample is 55 years (range 29-79), with a mean disease progression 9 years (4 months to 32 years). 70% are women. 33 patients (80.5%) initiated treatment with anti-TNF and 8 (19.5%) with other no anti-TNF mechanism of action. There was a statistically significant (p = 0.001, ANOVA) decrease in DAS 28 (average decrease of 1.6 points) at 3 months is maintained at 6 and 12 m and no significant differences in their evolution by separating anti-TNF drugs vs. other biological agents (different mechanisms of action (p = 0.285). So we have not detected a correlation between DAS 28 and FR or ACCP along the first 12 months of biological treatment. In our experience we did not find a correlation between DAS 28 and RF or ACCP, thus RF and ACCP do not appear to predict the response to treatment.
Cite this paper: A. Pereira, B. López, E. Naranjo and A. de la Serna, "Rheumatoid Factor and Anti Citrulinated Peptide. Relation with Remission and Progression in Rheumatoid Arthritis with Biologic Agent Therapy, during a One-Year Follow-Up," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 4 No. 1, 2014, pp. 34-38. doi: 10.4236/ojra.2014.41005.

[1]   R. Schrohenloher, S. J. Bridges and W. Koopman, “Rheumatoid Factor,” In: W. J. Koopmamn, Ed., Arthritis and Allied Conditions. A Textbook of Rheumatology. 13th Edition, Vol. 1, Willians & Wilkins, Baltimore, 1996, pp. 1109-1130.

[2]   G. A. Schellekens, B. A. de Jong, F. Van den Hoogen, L. van de Putte and W. van Venrooij, “Citrulline Is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-Specific Autoantibodies,” Journal of Clinical Investigation, Vol. 101, No. 1, 1998, pp. 273-281.

[3]   G. A. Schellekens, H. Visser, B. A. de jong, F. H. Van de Hoogen, J. M. Hazes, F. C. Breedveld, et al., “The Diagnosis Propietiers of Rheumatoid Arthritis Antibodies Recognizing a Cyclic Citrullinated Peptide,” Arthritis & Rheumatology, Vol. 43, No. 1, 2000, pp. 155-163.<155::AID-ANR20>3.0.CO;2-3

[4]   M. M. Nielen, D. Van Schaardenburg, H. W. Reesink, R. J. Van de Stadt, I. E. Van der Horst-Bruinsma, M. H. de Koning, et al., “Specific Autoantibodies Precede the Symptoms of Rheumatoid Arthritis. A Study of Serial Measurement in Blood Donors,” Arthritis & Rheumatology, Vol. 50, No. 2, 2004, pp. 380-386.

[5]   J. S. Smolen, A. Beauilieu, A. Rubbert-Rocth, C. Ramos-Remus, J. Rovensky, et al., “Effect of Interleukin-6 Receptor Inhibition with Tocilizumab in Patients with Rheumatoid Arthritis (OPTION Study) a Double-Blind Placebo Controlled Randomised Trial,” Lancet, Vol. 37, No. 9617, 2008, pp. 987-997.

[6]   J. M. Kremer, A. S. Russel, P. Emery, C. Abud-Mendoza, J. Szechinski, R. Westhovens, et al., “Long-Term Efficacy an Inhibition of Radiographic Progression with Abatacept Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 3 Years Results from the AIM Trial,” Annals of the Rheumatic Diseases, Vol. 70, No. 10, 2011, pp. 1826-1830.

[7]   M. Sebbag, M. Simon, C. Vincent, et al., “The Anti-Perinuclear Factor ant the So-Called Anti-Keratin Antibodies Are the Same Rheumatoid Arthritis-Specific Autoantibodies,” Journal of Clinical Investigation, Vol. 95, No. 6, 1995, pp. 2672-2679.

[8]   T. Senshu and G. Serre, “The Major Synovial Targets os the Rheumatoid Arthritis—Specific Anti-Filaggrin Autoantibodies Are Delaminated Forms of the Alpha and Beta-Chains os Fibrin,” Journal of Immunology, Vol. 66, 2001, pp. 4177-4184.

[9]   A. Ishigami and N. Maruyama, “Importance of Research on Peptidylarginine Deiminase and Citrullinated Proteins in Age-Related Disease,” Geriatrics & Gerontology International, Vol. 10, Suppl. 1, 2010, pp. S53-S58.

[10]   D. M. Lee and P. H. Schur, “Clinical Utility of the Anti CCP Assay in Patient with Rheumatoid Disease,” Annals of the Rheumatic Diseases, Vol. 62, No. 9, 2003, pp. 870-874.

[11]   A. Suzuki, R. Yamaha, X. Chang, S. Tokuhiro, T. Sawed, M. Suzuki, et al., “Functional Heliotypes of PAD14, Eroding Citrullinating Enzyme Peptidylarginine Deiminase 4, Are Associated with Rheumatoid Arthritis,” Nature Genetics, Vol. 34, 2003, 395-402.

[12]   K. N. Verpoort, C. M. Jol-van der Zijde, E. A. M. Papendrecht-van der Voort, A. Ioan Facsinay, J. W. Drijfhout and M. J. Van Tol, “Isotype Distribution of Anti Cyclic Citrullinnated Peptide Antibodies un Indifferentiated Arthritis and Rheumatoid Arthritis Reflects an Ongoing Immune Response,” Arthritis & Rheumatology, Vol. 54, No. 12, 2006, pp. 3799-3808.

[13]   P. De Pablo, I. L. C. Chspple, C. D. Buvkely and T. Dietrich, “Periodonditis in Systemic Rheumatic Disease,” Nature Reviews Rheumatology, Vol. 5, No. 4, 2009, pp. 218-224.

[14]   B. A. Fisher, D. Plant, K. Lundberg, P. Charles, A. Barton and P. J. Venables, “Heterogeneity of Citrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis,” Journal of Rheumatology, Vol. 39, No. 5, 2012, pp. 929-932.

[15]   H. Mahdi, B. A. Fisher, H. Kallberg, D. Plant, V. Malmstrom, J. Ronnelid, et al., “Specific Interaction between Genotype, Smoking and Autoimmunity to Citrullinated Alpha-Enolase in the Etiology of Rheumatoid Arthritis,” Nature Genetics, Vol. 41, 2009, pp. 1319-1324.

[16]   D. van der Woude, W. G. Alemayehu, W. Verduijn, R. R. de Vries, J. J. Houwing-Duistermaat, T. W. Huizinga, et al., “Gene-Environment Interaction Influences the Reactivity of Autoantibodies to Citrullinated Antigens in Rheumatoid Arthritis,” Nature Genetics, Vol. 42, 2010, pp. 814-816.

[17]   K. N. Verpoort, K. Cheung, A. Ioan-Facsinay, A. H. van der Helm-van Mil, J. K. de Vries-Bouwstra, C. F. Allaart, et al., “Fine Specificity of the Anti-Citrullinated Protein Antibody Response Is Influenced by the Shared Epitope Alleles,” Arthritis & Rheumatology, Vol. 56, No. 12, 2007, pp. 3949-3952.

[18]   C. Potter, K. L. Hyrich, A. Tracey, M. Lunt, D. Plant, D. P. Symmons, et al., “Association of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity, but Not Carriage of Shared Epitope or PTPN22 Susceptibility Variants, with Anti-Tumour Necrosis Factor Response in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 68, No. 1, 2009, pp. 69-74.

[19]   N. Wegner, K. Lundberg, A. Kinloch, B. Fisher, V. Malmstrom, M. Feldmann, et al., “Autoimmunity to Specific Citrullinated Proteins Gives the First Clues to the Etiology of Rheumatoid Arthritis,” Immunological Reviews, Vol. 233, No. 1, 2010, pp. 34-54.

[20]   C. Dejaco, C. Duftner, W. Klotz, M. Schirmer and M. Herold, “Third Generation Anti-Cyclic Citrullinated Peptide Antibodies Do Not Predict Anti-TNF. Alfa Treatment Response in Rheumatoid Arthritis,” Rheumatology International, Vol. 30, No. 4, 2010, pp. 451-454.

[21]   W. H. Bos, G. M. Bartelds, M. Vis, A. R. van der Horst, et al., “Preferential Decrease in IgG4 Anti-Citrullinated Protein Antibodies during Treatment with Tumor Necrosis Factor Blocking Agents in Patients with Rheumatoid Astrhitis,” Annals of the Rheumatic Diseases, Vol. 68, No. 4, 2009, pp. 558-563.

[22]   S. Rantapaa-Dahlqvist, B. A. W. De Jong, E. Berglin, et al., “Antibodies against Cyclic Citrullined Peptide and IgA Rheumatoid Factor Predict the Development of Rheumatoid Arthritis,” Arthritis & Rheumatology, Vol. 48, No. 10, 2003, pp. 2741-2749.

[23]   F. Bobbio-Pallavicini, R. Caporali, C. Alpini, R. Moratti and C. Montecucco, “Predictive Value of Antibodies to Citrullined Peptides and Rheumatoid Factors in Anti TNF Alpha Treated Patients,” Annals of the New York Academy of Sciences, Vol. 1109, 2007, pp. 287-295.

[24]   L. Mancarella, F. Bobbio-Pallavicini, F. Ceccarelli, P. C. Falappone, A. Ferrante, D. Malesci, et al., “Good Clinical Response, Remission, and Predictors of Remission in Rheumatoid Arthritis Patients Treated with Tumor Necrosis Factor-Alpha Clockers: The GISEA Study,” Journal of Rheumatology, Vol. 34, 2007, pp. 1670-1673.